EGRP News Flash - December 17, 2009

Innovative Molecular Analysis Technologies Program Funding Opportunity Announcements Re-Issued

On behalf of the National Cancer Institute's (NCI) Innovative Molecular Analysis Technologies Program (IMAT), the Epidemiology and Genetics Research Program (EGRP) announces the IMAT Funding Opportunity Announcements (FOAs) have been reissued for 2010 and released in the NIH Guide for Grants and Contracts.

The IMAT ProgramExternal Web Site Policy is aimed at stimulating and accelerating the development, integration, maturation, and dissemination of the most novel and highly innovative technologies in support of cancer research, detection, and diagnosis. Since 1998, the IMAT Program has accelerated the development of various tools, platforms, and associated methods that have direct relevance to cancer research and, ultimately, to clinical oncological practice. The IMAT Program consists of the following three related themes:

  1. Innovative Technology Development for Cancer Research (RFA-CA-10-005), which emphasizes technology development projects that are centered on the inception and preliminary development of very early stage, highly innovative, high impact technologies for cancer research;
  2. Emerging Technologies in Cancer Research (RFA-CA-10-003; RFA-CA-10-004), which supports research projects that are centered on the initial application or use of emerging, transformative technologies in a biological context relevant to the intended use of the technology; and
  3. Innovative and Applied Emerging Technologies in Biospecimen Science (RFA-CA-10-001; RFA-CA-10-002), which is centered on the development and validation of novel technologies to assess, evaluate, and interrogate biospecimens, or analytes thereof, in order to maximize their quality and utility in cancer research.

These technologies may be intended for molecular and cellular analyses in vitro, in situ, in silico, and/or in vivo (with some exceptions) and may be targeted for the needs of basic, translational, epidemiology, and/or clinical cancer research.

Projects in any area of cancer-related technology are encouraged provided that the technology proposed meets the requirement for the transformative potential. Technologies may target atomic, molecular, sub-cellular, and cellular levels of detection and analysis. General areas of interest include, but are not limited to, the following:

  • Technologies that enable substantially improved early cancer detection and cancer risk assessment;
  • Novel methods distinguishing, assessing, and monitoring cancer stage and progression;
  • Novel methods for deciphering basic mechanisms underlying cancer initiation and progression;
  • Robust technologies adapted for use in epidemiological research; and
  • Technologies or tools that address barriers pertaining to the incidence, prevalence, mortality, and burden of cancer among underserved populations.

Because the nature and scope of the proposed research will vary from application to application, it is anticipated that the size and duration of each award will also vary. Although the financial plans of the NCI provide support for the IMAT program, awards pursuant to these FOAs are contingent upon the availability of funds.

Letters of intent are due January 23, 2010; April 27, 2010; and August 30, 2010. Applications are due February 23, 2010; May 27, 2010; and September 30, 2010. The FOAs expire on October 1, 2010.

For general questions about cancer epidemiology, contact EGRP's Mukesh Verma, Ph.D., Chief, Methods and Technologies Branch.

Access the NIH Guide for Grants and Contracts:

Return to Top